

Media Release, April 26, 2019

BB Biotech AG reports results

In accordance with regulations on ad hoc publicity, BB Biotech AG is releasing the following information about its results of the interim financial statements as of March 31, 2019.

Based on consolidated results, BB Biotech AG reports for the first quarter a profit of CHF 890 mn (profit of CHF 28 mn in the corresponding period of the previous year) was incurred. As an investment company, the result reflects the performance of the stocks it holds in its investment portfolio.

Since beginning of the year, BB Biotech AG's share price increased 24.2% in CHF and 25.4% in EUR.

The interim report as of March 31, 2019 will be published on April 26, 2019 at 7 am.

For further information:

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland
Tanja Chicherio, Tel. +41 44 267 67 07, tch@bellevue.ch

www.bbbiotech.com

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.